Cynthia Lyle Kelly

Cynthia Lyle Kelly is an accomplished professional in the biopharmaceutical industry with extensive experience in program leadership and clinical operations. Currently serving as Senior Director, Program Leadership at Turnstone Biologics since 2022, Cynthia previously held the position of Senior Director, Early Development Program Lead in Cardiovascular at Bristol Myers Squibb from 2020 to 2022. Prior to that role, Cynthia was Project Team Leader for Danicamtiv (MYK-491) at MyoKardia from 2017 to 2020, where leadership included the development of therapeutic strategies and oversight of clinical operations. Cynthia also contributed as a founding member of the MyoKardia Women's Forum Steering Committee. Earlier career experience includes roles at Medivation, Quintiles, the University of California, Sandia National Laboratories, and Arbor Vita Corporation. Cynthia holds a PhD in Cancer Biology from the University of California, San Francisco, and a BS in Cellular and Molecular Biology from Tulane University.